Evidence map›Paper›PMID 37237744›Full record

ArticleAntibiotics (Basel, Switzerland)2023

Randomized Clinical Trial of the Need for Antibiotic Treatment for Low-Risk Catheter-Related Bloodstream Infection Caused by Coagulase-Negative Staphylococci.

Laia Badia-Cebada, João Carmezim, María-Teresa Pérez-Rodríguez, Elena Bereciartua, Luis-Eduardo López, Marta Represa Montenegro, Virginia Pomar, Marta Andrés, Elizabet Petkova, Nieves Sopena and 8 more

Open access · goldAbstract read
In one paragraph

Article in Antibiotics (Basel, Switzerland), 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
2.2field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 6 citations in OpenAlex.

  1. Review
  2. Article
  3. Validation of the Proposed Definition for Complicated Coagulase-negative Staphylococcal Bacteremia.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2025
    Article
  4. Article
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors at 11 institutions in 1 country.

Laia Badia-CebadaInternal Medicine Department, Hospital Universitari Parc Taulí, Institut d'investigació i innovació Parc Taulí, Universitat Autònoma de Barcelona, 08208 Sabadell, Spain.
João CarmezimUnit of Statistics, Hospital Universitari de Bellvitge/Institut d'Investigació Biomèdica de Bellvitge-IDIBELL, 08908 L'Hospitalet de Llobregat, Spain.
María-Teresa Pérez-RodríguezInfectious Diseases Unit, Department of Internal Medicine. Hospital Álvaro Cunqueiro, Galicia Sur Health Research Institute, 36312 Vigo, Spain.ORCID 0000-0003-2944-8610
Elena BereciartuaInfectious Diseases Unit, Hospital Universitario de Cruces, 48903 Barakaldo, Spain.ORCID 0000-0002-8603-779X
Luis-Eduardo LópezInfectious Diseases and Microbiology Clinical Unit, University Hospital Virgen Macarena, 41009 Seville, Spain.ORCID 0000-0002-9347-527X
Marta Represa MontenegroInfectious Diseases Unit, Department of Internal Medicine. Hospital Álvaro Cunqueiro, Galicia Sur Health Research Institute, 36312 Vigo, Spain.
Virginia PomarInfectious Diseases Unit, Department of Internal Medicine, Hospital de la Santa Creu I Sant Pau, 08025 Barcelona, Spain.ORCID 0000-0002-8473-5834
Marta AndrésInfectious Diseases Unit, Department of Internal Medicine, Hospital Consorci de Terrassa, 08227 Terrassa, Spain.
Elizabet PetkovaInfectious Diseases Unit, Department of Internal Medicine, Hospital Universitario Fundación Jiménez Díaz, 28040 Madrid, Spain.
Nieves SopenaInfectious Diseases Department Hospital Germans Trias i Pujol, 08916 Badalona, Spain.
Jaime Lora-TamayoCenter for Biomedical Research in Infectious Diseases Network (CIBERINFEC), Instituto de Salud Carlos III, 28029 Madrid, Spain.
Víctor MonsálvezInternal Medicine Department, Hospital Universitari Parc Taulí, Institut d'investigació i innovació Parc Taulí, Universitat Autònoma de Barcelona, 08208 Sabadell, Spain.
Maria Fernanda Ramirez-HidalgoNosocomial Infections Departmen, Arnau de Vilanova University Hospital, 08202 Lleida, Spain.
Silvia Gómez-ZorrillaCenter for Biomedical Research in Infectious Diseases Network (CIBERINFEC), Instituto de Salud Carlos III, 28029 Madrid, Spain.ORCID 0000-0002-5987-068X
Lucía BoixInfectious Diseases Department, Hospital Universitari Mútua Terrassa, 08221 Terrassa, Spain.
Yolanda MeijeInfectious Diseases Unit, Department of Internal Medicine. Hospital de Barcelona, 08034 Barcelona, Spain.
Emili JiménezInfectious Diseases Department, Hospital Universitari de Bellvitge, Institut d'Investigació Biomèdica de Bellvitge-IDIBELL, 08907 L'Hospitalet de Llobregat, Spain.
Oriol GaschInfectious Diseases Department, Hospital Universitari Parc Taulí. Institut d'investigació i Innovació Parc Taulí, Universitat Autònoma de Barcelona, 08193 Sabadell, Spain.
Universitat Autònoma de Barcelona · ESBellvitge University Hospital · ESInstituto de Salud Carlos III · ESConsorci Sanitari de Terrassa · ESHospital de Cruces · ESHospital de Sant Pau · ESHospital Universitari Arnau de Vilanova · ESHospital Universitari Germans Trias i Pujol · ESHospital Universitario Fundación Jiménez Díaz · ESUniversitat Internacional de Catalunya · ESUniversitat Pompeu Fabra · ES

Funding

Institute of Research and Innovation Parc Tauli CIR2017/053 and CIR2018/039.
6 · The paper itself

Abstract

According to clinical guidelines, the management of catheter-related bloodstream infections (CRBSI) due to coagulase-negative staphylococci (CoNS) includes catheter removal and antibiotic treatment for 5 to 7 days. However, in low-risk episodes, it remains uncertain whether antibiotic therapy is necessary. This randomized clinical trial aims to determine whether the non-administration of antibiotic therapy is as safe and effective as the recommended strategy in low-risk episodes of CRBSI caused by CoNS. With this purpose, a randomized, open-label, multicenter, non-inferiority clinical trial was conducted in 14 Spanish hospitals from 1 July 2019 to 31 January 2022. Patients with low-risk CRBSI caused by CoNS were randomized 1:1 after catheter withdrawal to receive/not receive parenteral antibiotics with activity against the isolated strain. The primary endpoint was the presence of any complication related to bacteremia or to antibiotic therapy within 90 days of follow-up. The secondary endpoints were persistent bacteremia, septic embolism, time until microbiological cure, and time until the disappearance of a fever. EudraCT: 2017-003612-39 INF-BACT-2017. A total of 741 patients were assessed for eligibility. Of these, 27 were included in the study; 15 (55.6%) were randomized to the intervention arm (non-antibiotic administration) and 12 (44.4%) to the control arm (antibiotic therapy as per standard practice). The primary endpoint occurred in one of the 15 patients in the intervention group (septic thrombophlebitis) and in no patients in the control group. The median time until microbiological cure was 3 days (IQR 1-3) in the intervention arm and 1.25 days (IQR 0.5-2.62) in the control arm, while the median time until fever resolution was zero days in both arms. The study was stopped due to the insufficient number of recruited patients. These results seem to indicate that low-risk CRBSI caused by CoNS can be managed without antibiotic therapy after catheter removal; efficacy and safety are not affected.

Indexed as

antibiotic stewardshipcatheter-related bloodstream infectioncoagulase-negative staphylococcihealthcare related infection

Identifiers

PMID37237744
PMCPMC10215141
OpenAlexW4367623997

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.